Literature DB >> 22229212

Resection for thoracic metastases from sarcoma.

Zachary Kon1, Linda Martin.   

Abstract

Sarcoma metastasizes to the lungs in 20% to 40% of patients and in most cases does not involve any other organ. Systemic chemotherapy is of unproven benefit for stage IV sarcoma. Retrospective studies have shown 5-year survival rates of 21% to 38% with wedge resection of metastatic pulmonary nodules, and up to 30% to 40% of patients survive an additional 5 years with repeated metastasectomy. In this article, we provide an extensive review of patient selection criteria and surgical approaches, as well as of controversies regarding resection for metastatic sarcoma.

Entities:  

Mesh:

Year:  2011        PMID: 22229212

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  4 in total

Review 1.  Pulmonary metastasectomy: role of pulmonary metastasectomy and type of surgery.

Authors:  Francis C Nichols
Journal:  Curr Treat Options Oncol       Date:  2014-09

Review 2.  Survival and prognostic factors following pulmonary metastasectomy for sarcoma.

Authors:  Giuseppe Marulli; Marco Mammana; Giovanni Comacchio; Federico Rea
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

3.  Epidemiology and therapies for metastatic sarcoma.

Authors:  Ernest K Amankwah; Anthony P Conley; Damon R Reed
Journal:  Clin Epidemiol       Date:  2013-05-16       Impact factor: 4.790

4.  Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma.

Authors:  Niraj Mehta; Michael Selch; Pin-Chieh Wang; Noah Federman; Jay M Lee; Fritz C Eilber; Bartosz Chmielowski; Nzhde Agazaryan; Michael Steinberg; Percy Lee
Journal:  Sarcoma       Date:  2013-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.